DK3300729T3 - Terapeutiske sammensætninger indeholdende macitentan - Google Patents

Terapeutiske sammensætninger indeholdende macitentan Download PDF

Info

Publication number
DK3300729T3
DK3300729T3 DK17191033.4T DK17191033T DK3300729T3 DK 3300729 T3 DK3300729 T3 DK 3300729T3 DK 17191033 T DK17191033 T DK 17191033T DK 3300729 T3 DK3300729 T3 DK 3300729T3
Authority
DK
Denmark
Prior art keywords
compositions containing
therapeutic compositions
containing macitentan
macitentan
therapeutic
Prior art date
Application number
DK17191033.4T
Other languages
English (en)
Inventor
Martine Clozel
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41346591&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3300729(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Application granted granted Critical
Publication of DK3300729T3 publication Critical patent/DK3300729T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DK17191033.4T 2008-08-13 2009-08-12 Terapeutiske sammensætninger indeholdende macitentan DK3300729T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2008053252 2008-08-13
EP09786912.7A EP2315587B1 (en) 2008-08-13 2009-08-12 Therapeutic compositions containing macitentan

Publications (1)

Publication Number Publication Date
DK3300729T3 true DK3300729T3 (da) 2020-01-20

Family

ID=41346591

Family Applications (2)

Application Number Title Priority Date Filing Date
DK17191033.4T DK3300729T3 (da) 2008-08-13 2009-08-12 Terapeutiske sammensætninger indeholdende macitentan
DK09786912.7T DK2315587T3 (da) 2008-08-13 2009-08-12 Terapeutiske sammensætninger indeholdende macitentan

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK09786912.7T DK2315587T3 (da) 2008-08-13 2009-08-12 Terapeutiske sammensætninger indeholdende macitentan

Country Status (29)

Country Link
US (3) US8809334B2 (da)
EP (2) EP2315587B1 (da)
JP (3) JP5764061B2 (da)
KR (1) KR101678699B1 (da)
CN (1) CN102099026B (da)
AR (1) AR073031A1 (da)
AU (1) AU2009280843B2 (da)
BR (1) BRPI0917661B8 (da)
CA (1) CA2731370C (da)
CY (2) CY1119826T1 (da)
DK (2) DK3300729T3 (da)
ES (2) ES2763176T3 (da)
HK (1) HK1253355B (da)
HR (2) HRP20171917T1 (da)
HU (2) HUE036071T2 (da)
IL (1) IL211143A0 (da)
LT (2) LT2315587T (da)
MA (1) MA32614B1 (da)
MX (1) MX350011B (da)
MY (1) MY178894A (da)
NO (1) NO2315587T3 (da)
NZ (1) NZ591601A (da)
PL (2) PL2315587T3 (da)
PT (2) PT2315587T (da)
RU (1) RU2519161C2 (da)
SI (2) SI3300729T1 (da)
TW (1) TWI446911B (da)
WO (1) WO2010018549A2 (da)
ZA (1) ZA201101900B (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1928409T1 (sl) 2005-09-12 2012-12-31 Actelion Pharmaceuticals Ltd. Stabilni farmacevtski sestavek, ki obsega pirimidin-sulfamid
MX2010001837A (es) 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Derivados de 4-pirimidinasulfamida.
AU2009218115B2 (en) * 2008-02-28 2013-05-30 Nippon Shinyaku Co., Ltd. Fibrosis inhibitor
PT2315587T (pt) 2008-08-13 2018-01-31 Actelion Pharmaceuticals Ltd Produto que contém macitentan, composição farmacêutica que o contém e uso de macitentan
JP6542128B2 (ja) 2013-01-11 2019-07-10 コルセア ファーマ インコーポレイテッド トレプロスチニルのプロドラッグ
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US9643911B2 (en) 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9794795B1 (en) 2016-04-29 2017-10-17 Corning Optical Communications Wireless Ltd Implementing a live distributed antenna system (DAS) configuration from a virtual DAS design using an original equipment manufacturer (OEM) specific software system in a DAS
EP3554507A1 (en) 2016-12-14 2019-10-23 Respira Therapeutics, Inc. Methods and compositions for treatment of pulmonary hypertension and other lung disorders
AU2019410727A1 (en) * 2018-12-21 2021-08-12 Actelion Pharmaceuticals Ltd Pharmaceutical composition for the treatment of pulmonary arterial hypertension
TW202042818A (zh) 2019-01-25 2020-12-01 瑞士商艾克泰聯製藥有限公司 用於治療慢性血栓性肺高血壓之醫藥組成物
CA3161960A1 (en) 2019-12-16 2021-06-24 Tenax Therapeutics, Inc. Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (ph-hfpef)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4539333A (en) 1976-05-11 1985-09-03 Burroughs Wellcome Co. Prostacyclin, methods of using and method of making
DE2845770A1 (de) 1978-10-19 1980-04-30 Schering Ag Neue prostacyclin-derivate und verfahren zu ihrer herstellung
JPS58124778A (ja) 1982-01-20 1983-07-25 Toray Ind Inc ５，６，７−トリノル−４，８−インタ−ｍ−フエニレンＰＧＩ↓２誘導体
US4683330A (en) 1984-03-08 1987-07-28 The Upjohn Company Interphenylene carbacyclin derivatives
US7094781B2 (en) * 2000-12-18 2006-08-22 Actelion Pharmaceuticals Ltd. Sulfamides and their use as endothelin receptor antagonists
MXPA03005393A (es) * 2000-12-19 2003-09-25 Merck Patent Gmbh Formulacion farmaceutica que contiene pirazolo (4,3-d) pirimidinas y antitromboticos, antagonistas de calcio, prostaglandinas o derivados de prostaglandina.
DE10100426B4 (de) 2001-01-08 2006-04-06 Steag Hamatech Ag Verfahren und Vorrichtung zum Zusammenfügen von Substraten
TWI316055B (da) * 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
WO2004017993A1 (en) * 2002-08-12 2004-03-04 Actelion Pharmaceuticals Ltd Combination of prostacyclin or prostacyclin analogues and endothelin receptor antagonists for the treatment of pulmonary arterial hypertension
KR101063042B1 (ko) 2002-12-02 2011-09-07 액테리온 파마슈티칼 리미티드 피리미딘-설파마이드 및 엔도텔린 수용체 길항제로서이들의 용도
US20050101608A1 (en) * 2003-09-24 2005-05-12 Santel Donald J. Iloprost in combination therapies for the treatment of pulmonary arterial hypertension
TW200628467A (en) * 2004-11-11 2006-08-16 Actelion Pharmaceuticals Ltd Novel sulfamides
SI1928409T1 (sl) 2005-09-12 2012-12-31 Actelion Pharmaceuticals Ltd. Stabilni farmacevtski sestavek, ki obsega pirimidin-sulfamid
AR062501A1 (es) 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
TWI441639B (zh) 2008-02-20 2014-06-21 Actelion Pharmaceuticals Ltd 用於治療卵巢癌之包含紫杉醇之組合
PT2315587T (pt) 2008-08-13 2018-01-31 Actelion Pharmaceuticals Ltd Produto que contém macitentan, composição farmacêutica que o contém e uso de macitentan

Also Published As

Publication number Publication date
BRPI0917661B8 (pt) 2021-05-25
HK1253355B (zh) 2020-06-19
HRP20171917T1 (hr) 2018-02-09
US8809334B2 (en) 2014-08-19
AU2009280843A1 (en) 2010-02-18
HK1253355A1 (zh) 2019-06-14
US20160022678A1 (en) 2016-01-28
JP5956026B2 (ja) 2016-07-20
SI3300729T1 (sl) 2020-02-28
TWI446911B (zh) 2014-08-01
WO2010018549A3 (en) 2010-07-29
US20140329824A1 (en) 2014-11-06
DK2315587T3 (da) 2018-01-02
LT3300729T (lt) 2020-01-10
CN102099026A (zh) 2011-06-15
EP2315587A2 (en) 2011-05-04
HUE047767T2 (hu) 2020-05-28
WO2010018549A2 (en) 2010-02-18
BRPI0917661B1 (pt) 2019-12-17
JP2015180683A (ja) 2015-10-15
KR20110045006A (ko) 2011-05-03
EP2315587B1 (en) 2017-10-25
JP5956025B2 (ja) 2016-07-20
HRP20192204T1 (hr) 2020-03-06
MA32614B1 (fr) 2011-09-01
SI2315587T1 (en) 2018-04-30
RU2011109084A (ru) 2012-09-20
MX350011B (es) 2017-08-22
PL3300729T3 (pl) 2020-04-30
ZA201101900B (en) 2012-08-29
KR101678699B1 (ko) 2016-11-23
RU2519161C2 (ru) 2014-06-10
HUE036071T2 (hu) 2018-06-28
US9173881B2 (en) 2015-11-03
CN102099026B (zh) 2012-08-29
EP3300729A1 (en) 2018-04-04
PL2315587T3 (pl) 2018-03-30
PT2315587T (pt) 2018-01-31
AU2009280843B2 (en) 2015-03-05
JP5764061B2 (ja) 2015-08-12
CA2731370C (en) 2017-03-14
LT2315587T (lt) 2018-01-10
CY1119826T1 (el) 2018-06-27
ES2763176T3 (es) 2020-05-27
NZ591601A (en) 2012-12-21
JP2015187148A (ja) 2015-10-29
IL211143A0 (en) 2011-04-28
TW201010985A (en) 2010-03-16
CA2731370A1 (en) 2010-02-18
US9597331B2 (en) 2017-03-21
AR073031A1 (es) 2010-10-06
US20110136818A1 (en) 2011-06-09
ES2652590T3 (es) 2018-02-05
EP3300729B1 (en) 2019-10-09
MY178894A (en) 2020-10-21
MX2011001625A (es) 2011-03-29
NO2315587T3 (da) 2018-03-24
CY1122641T1 (el) 2021-03-12
JP2011530581A (ja) 2011-12-22
PT3300729T (pt) 2020-01-20
BRPI0917661A2 (pt) 2015-12-01

Similar Documents

Publication Publication Date Title
BRPI1011587A2 (pt) compostos e composições terapèuticas
DK2634231T3 (da) Sammensætninger
BRPI0906749A2 (pt) Composição
BRPI0913808A2 (pt) composição
DE602008002756D1 (de) Bauzusammensetzung
HK1253355A1 (zh) 含有馬西替坦的治療組合物
BRPI0810634A2 (pt) Composições fungicidas
BRPI0914746A2 (pt) composições fungicidas
ES2628203T8 (es) Composiciones antitranspirantes
IT1392101B1 (it) Composizione comprendente isoflavoni
BRPI0813775A2 (pt) Composição
BRPI0917231A2 (pt) composição
ATE528048T1 (de) Schweisshemmende/desodorierende zusammensetzung
FR2933868B1 (fr) Compositions cosmetiques
DK2285413T3 (da) Farmaceutisk sammensætning
BRPI0810557A2 (pt) composição
BRPI0811274A2 (pt) Composição
BRPI0921313A2 (pt) composição farmaucêutica
DK2966175T3 (da) Farmaceutiske sammensætninger indeholdende cortexolon-17-alpha-propionat
BRPI0811002A2 (pt) Composição biofertilizante
BRPI0912171A2 (pt) composição farmacêutica
BRPI0809270A2 (pt) Composição
BRPI0921301A2 (pt) composição farmacêutica
BRPI0917584A2 (pt) composição
BRPI0909764A2 (pt) compostos terapêuticos